News & Innovations

News and innovations published by German exhibitors

  back to overview

Discovery of a neutralizing antibody to treat Covid-19

Fast track development of SARS-CoV-2 antibody (6 months).

In less than six months, an antibody gene library was generated, screened against SARS-CoV-2 S1 protein and a fi nal lead molecule (COR-101) was identifi ed by a set of selected assays including life virus neutralization and CMC assessment YUMAB‘s antibody discovery and development platform identifi ed several promising candidates with high affi nity, very good developability prediction and binding to most presently known SARS-CoV-2 variants.

Antibodies expressed at GMP standards after stable cell line development show a high expression titer and exhibit good developability.

Exhibitor: YUMAB GmbH


We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection